22nd International Conference on Alzheimer's Drug Discovery

To be held online October 4-5, 2021.

Access to the virtual sessions (lectures and short presentations) will require registration.


If you have registered before noon on October 3, 2021, you should have received instructions to access the virtual hub of our conference (check your spam folders, as well!).


You can access the virtual hub of the conference with the email address used to register for the event. If you have accessed our meetings of last year, you should connect with the password you set at that time. If, however, you do not remember that password or are logging in for the first time, simply click on “Forgot password” and then look for an email from us with instructions (once more, please check your spam box).

This annual conference showcases the innovative approaches of Alzheimer’s Drug Discovery Foundation’s (ADDF) funded scientists and their newest results. In addition to featuring ADDF’s portfolio, the program also includes guest presentations focusing on the latest research in the Alzheimer’s disease field.


The 2021 program will feature five sessions:

  1. Clinical Trials and Novel Approaches for Dementia
  2. Advances in Fluid Biomarkers
  3. Drug Development Approaches for Frontotemporal Dementia
  4. Clinical Trials: Repurposing Approaches for Alzheimer’s Disease
  5. Neuroimaging and Digital Biomarkers for Dementia


The registration for this conference will be free though a brief form available at the Registration page.


  • Highlight scientific progress on drug development and biomarker programs aimed at treating Alzheimer’s disease and related dementias.
  • Increase opportunities for early career investigators and start-up companies to share information and resources.
  • Foster interdisciplinary and public-private partnerships and alliances.


22 Speakers

Virtual Poster Presentations

Start-up Forum

Virtual Q&A

Ample sponsorship opportunities

Complimentary Registration


The purpose for this annual ADDF conference is to accelerate the development of innovative treatments for Alzheimer’s disease, related dementias and cognitive aging.

Attendees will see the diverse cutting-edge approaches ADDF scientists are undertaking and have opportunities for networking and partnership discussions with academic, industry, and foundation thought leaders.


The 2020 edition of this conference attracted close to 900 attendees from around the world.  Attendees included:

  • Academic and industry scientists engaged in drug discovery and biomarker research for neurodegenerative diseases and CNS
  • Business development and licensing professionals
  • Alliance management professionals
  • Venture capitalists and other investors
  • Graduate students, PhD candidates and post-doctoral fellows.


Ottavio Arancio
Columbia University

Rhoda Au
Boston University

Dirk Beher


Kaj Blennow
Univ. of Gothenburg

Wen-Hsuan Chang

Jeffrey Cummings

Penny Dacks

Howard Fillit

Ihab Hajjar
Emory University

Jonathan Jackson
MGH/Harvard Univ.

Miia Kivipelto
Karonlinska Inst.

Lampros Kourtis

Russell Lebovitz

Frank Longo

Gladys Maestre

Qinwen Mao
Univ. of Utah

Mark Mintun
Eli Lilly & Co., Inc.

Thomas Montine
Stanford Univ.

Miranda Orr
Wake Forest Univ.

Shobha Purushothama

Jason Resendez

Jonathan Sabbagh

Tracy Saxton
Dolby Family Ventures

Emiliano Santarnecchi
Harvard Medical School

Christy Sheehy
C. Light Technologies

Georg Terstappen
Cambrian Biopharma

Alessio Travaglia

Kent Werner
Cogentis Therapeutics

Kevin Yarasheski
C2N Diagnostics

Join us today!

Reserve a virtual seat at the conference, consider sponsoring the event,
submitting an application for a virtual poster or start-up presentation or simply, spread the word about it!